Profile
Stefan Braam was the founder of Pluriomics BV, where he held the title of Chief Executive Officer.
He is also the founder of Cellistic, where he currently holds the titles of President, Chief Technology Officer & Director.
Cellistic was founded in 2022.
Dr. Braam is also the founder of Ncardia SA. Currently, he is the Managing Director & Director at Ncardia Holding SA, a position he has held since 2015.
Stefan Braam active positions
| Companies | Position | Start |
|---|---|---|
Ncardia SA
 Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Founder | - |
Cellistic
 Cellistic BiotechnologyHealth Technology Part of Ncardia SA, Cellistic is a subsidiary that specializes in the process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The Belgian company's focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development make it an ideal partner for innovative cell therapy developers to commercialize novel advanced therapies. The company was founded by Stefan Braam, and Gustavo Mahler has been the CEO of the company since 2023. | Founder | 2022-03-31 |
Ncardia Holding SA
 Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | Chief Executive Officer | 2021-11-12 |
Former positions of Stefan Braam
| Companies | Position | End |
|---|---|---|
Pluriomics BV
 Pluriomics BV BiotechnologyHealth Technology Pluriomics BV provides cardiac drug discovery and safety assessment solutions. The company was founded by Stefan Braam, Christine Mummery, Robert Passier and Herman Spolders in 2010 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Pluriomics BV
Pluriomics BV BiotechnologyHealth Technology Pluriomics BV provides cardiac drug discovery and safety assessment solutions. The company was founded by Stefan Braam, Christine Mummery, Robert Passier and Herman Spolders in 2010 and is headquartered in Leiden, the Netherlands. | Health Technology |
Ncardia SA
Ncardia SA Miscellaneous Commercial ServicesCommercial Services Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium. | Commercial Services |
Ncardia Holding SA
Ncardia Holding SA BiotechnologyHealth Technology Ncardia Holding SA provides biotech research and development, business management consulting, technical testing, and administrative services. The private company is based in Mont-Saint-Guibert, Belgium. The Belgian company was founded in 2014. Stefan Braam has been the CEO of the company since 2015. | Health Technology |
Cellistic
Cellistic BiotechnologyHealth Technology Part of Ncardia SA, Cellistic is a subsidiary that specializes in the process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The Belgian company's focus and expertise in iPSC reprogramming, differentiation, and expansion protocol development make it an ideal partner for innovative cell therapy developers to commercialize novel advanced therapies. The company was founded by Stefan Braam, and Gustavo Mahler has been the CEO of the company since 2023. | Health Technology |
- Stock Market
- Insiders
- Stefan Braam
